Eli Lilly stops Phase II trial of BTK inhibitor in RA

Eli Lilly and Co. (NYSE:LLY) discontinued the Phase II RAjuvenate trial of HM71224 (LY3337641) to treat rheumatoid arthritis after a planned analysis showed that the difference between the active and placebo control arms "was not sufficient enough" to support continuation of the trial, spokesperson Nicole Hebert told BioCentury.

Lilly shares rights to the oral Bruton's tyrosine kinase (BTK) inhibitor with Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940) under a 2015 deal. Hebert said the agreement remains in place and that the partners are discussing next steps for HM71224...